Nuevolution A/S (Copenhagen, Denmark) is a drug discovery company dedicated to revolutionize fragment- and high throughput-based lead discovery.

The company’s drug discovery platform, Chemetics™, excels at being more cost-efficient, faster and better than conventional methods in identifying drug leads to virtually any therapeutic target.

Nuevolution is successfully exploiting its platform technology both through internal programs, fully partner-funded programs and through collaborative projects.

Nuevoloution was acquired by Amgen in 2019

For more information, please contact:

Søren Lemonius, Msc

Managing General Partner

Phone: +45 4081 4889